Circulating sphingolipids, fasting glucose, and impaired fasting glucose: The Strong Heart Family Study

Abstract

Background Animal studies suggest sphingolipids as an early marker of impaired glucose metabolism; however, research in humans is limited. We evaluated whether individual sphingolipid species were associated with fasting plasma glucose and incident impaired fasting glucose in a longitudinal cohort study. Methods We measured 15 sphingolipid species from blood samples collected in 2001–2003 from 2145 participants without prevalent diabetes in the Strong Heart Family Study. Fasting plasma glucose was measured in blood samples collected at baseline and follow-up (mean 5.5 years after baseline). Findings The average age of study participants was 38 years; 41% were men. Ceramide, sphingomyelin, and glucosylceramide species levels were higher in older participants; lactosyl-ceramide levels were higher in participants with lower BMIs. In adjusted analyses, greater concentrations of most ceramide species and lower lactosyl-ceramide with palmitic acid (LC-16) were associated with higher glucose levels at baseline. We did not observe associations of sphingomyelin species or glucosyl-ceramide species with glucose levels. Associations of sphingolipid levels with fasting glucose levels at follow-up were similar but had greater uncertainty than associations with baseline glucose. Although no statistically significant associations of sphingolipids with incident impaired fasting glucose were present, results were similar to glucose analyses. Interpretation We identified several ceramide species associated with higher fasting glucose levels and one sphingolipid, LC-16, that was associated with lower fasting glucose levels. These findings compliment previous research, which linked these sphingolipids with fasting insulin levels, and suggest that higher levels of these ceramides and lower LC-16 may be an early marker of impaired glucose metabolism. Fund US National Institutes Health.

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

“…Over the last few years, circulating sphingolipids have been gaining interest as predictive biomarkers for cardiac and metabolic disorders. Consistently, recent findings have shown that altered circulating sphingolipids were associated with defective insulin signaling [255][256][257][258][259]. The ability of sphingolipids to be trafficked from tissue to tissue using plasma lipoprotein carriers would also reveal a role for interorgan crosstalk.…”

Serum biomarkers from cell-based assays for AhRL and MIS strongly predicted the future development of diabetes in a large community-based prospective study in Korea

“…The ORs for diabetic risk genes were less than 1.7 in genome-wide association studies 36 . A 2-fold higher ceramide-24 level was associated with 1.45 times higher risk of incident impaired fasting glucose 37 . We believe that an important factor in explaining why RRs in this study were so high was the measurement of AhRL and MIS with the cell-based bioassays.…”

Integrative Epigenomic and Transcriptomic Analysis Reveals Robust Metabolic Switching in the Brain During Intermittent Fasting

“…Indeed, global metabolic mapping revealed different metabolic profiles in IF16 and EOD, with asymmetrical trigger of different milieu of carbohydrate, lipid, and protein cellular metabolic pathways, as well as performing varying degrees of anabolism and catabolism of these macromolecules. While most of the signalling pathways have been previously reported to be influenced by fasting (Ahima et al, 2006;Bujak et al, 2015;Choi et al, 2018;Dogan et al, 2011;Goldstein et al, 2016;Guo et al, 2016;Jensen et al, 2019;Kim, 2009;Li et al, 2019;Luo et al, 2018;Mahadik, 2012;Martins et al, 2016;Miyazaki et al, 2004;Morikawa et al, 2004;Nicklin et al, 2013;Pel and Lines, 2015;Rodrı et al, 2012;Tulsian et al, 2018;Wee and Wang, 2017;Wijngaarden et al, 2019;Yoon et al, 2018), our findings suggest a temporal link of the signaling response to the period of energy restriction. This is achieved by manipulating the epigenetic and transcriptomic cascade differently, which in turn results in varied metabolic arms being triggered to respond to energy demand.…”